PARP1 and urinary bladder cancer: We found regorafenib significantly induces apoptosis and increases activation of Fas/FasL, Caspase‐8, ‐3, loss of ΔΨm, and cleavage of PARP1 in bladder cancer TSGH 8301 cells.